Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (221-230 of 323) with videos related to

Pageof 33
Sort By:
Leukemia & Lymphoma|January 30, 2020
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemiaJorge J Castillo, Gilad Itchaki, Joshua N Gustine, et al.
Blood|March 5, 2008
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemiaAldo M Roccaro, Xavier Leleu, Antonio Sacco, et al.
Blood Advances|January 15, 2020
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomasXia Liu, Jiaji G Chen, Manit Munshi, et al.
Future Oncology (London, England)|July 29, 2024
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trialAlessandra Tedeschi, Constantine S Tam, Roger G Owen, et al.
Blood Advances|December 29, 2021
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapyJorge J Castillo, Shayna R Sarosiek, Joshua N Gustine, et al.
Blood|May 5, 2016
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinibGuang Yang, Sara J Buhrlage, Li Tan, et al.
Clinical Lymphoma & Myeloma|April 28, 2006
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's MacroglobulinemiaEva Kimby, Steven P Treon, Athanasios Anagnostopoulos, et al.
Blood|February 8, 2007
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemiaAnne-Sophie Moreau, Xiaoying Jia, Hai T Ngo, et al.
British Journal of Haematology|July 6, 2016
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström MacroglobulinaemiaJorge J Castillo, Ramon Garcia-Sanz, Evdoxia Hatjiharissi, et al.
British Journal of Haematology|September 6, 2018
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemiaJoshua N Gustine, Nicholas Tsakmaklis, Maria G Demos, et al.
Pageof 33

Showing results (221-230 of 323) with videos related to

Sort By:
Pageof 33
Leukemia & Lymphoma|January 30, 2020
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemiaJorge J Castillo, Gilad Itchaki, Joshua N Gustine, et al.
Blood|March 5, 2008
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemiaAldo M Roccaro, Xavier Leleu, Antonio Sacco, et al.
Blood Advances|January 15, 2020
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomasXia Liu, Jiaji G Chen, Manit Munshi, et al.
Future Oncology (London, England)|July 29, 2024
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trialAlessandra Tedeschi, Constantine S Tam, Roger G Owen, et al.
Blood Advances|December 29, 2021
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapyJorge J Castillo, Shayna R Sarosiek, Joshua N Gustine, et al.
Blood|May 5, 2016
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinibGuang Yang, Sara J Buhrlage, Li Tan, et al.
Clinical Lymphoma & Myeloma|April 28, 2006
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's MacroglobulinemiaEva Kimby, Steven P Treon, Athanasios Anagnostopoulos, et al.
Blood|February 8, 2007
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemiaAnne-Sophie Moreau, Xiaoying Jia, Hai T Ngo, et al.
British Journal of Haematology|July 6, 2016
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström MacroglobulinaemiaJorge J Castillo, Ramon Garcia-Sanz, Evdoxia Hatjiharissi, et al.
British Journal of Haematology|September 6, 2018
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemiaJoshua N Gustine, Nicholas Tsakmaklis, Maria G Demos, et al.
Pageof 33